Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) COO Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Thursday, January 26th. The shares were sold at an average price of $8.07, for a total transaction of $64,560.00. Following the sale, the chief operating officer now owns 203,654 shares of the company's stock, valued at $1,643,487.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Tina Marriott Larson also recently made the following trade(s):
Get Recursion Pharmaceuticals alerts:- On Thursday, December 29th, Tina Marriott Larson sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.70, for a total transaction of $61,600.00.
- On Thursday, November 17th, Tina Marriott Larson sold 16,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.96, for a total transaction of $175,360.00.
Recursion Pharmaceuticals Stock Up 4.3 %
Shares of NASDAQ RXRX opened at $8.54 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.92 and a 52 week high of $14.18. The firm's fifty day moving average is $8.41 and its 200 day moving average is $9.77.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last issued its earnings results on Tuesday, November 8th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.01. Recursion Pharmaceuticals had a negative net margin of 860.34% and a negative return on equity of 53.04%. The company had revenue of $13.16 million for the quarter, compared to the consensus estimate of $6.43 million. Equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.4 EPS for the current fiscal year.Analysts Set New Price Targets
A number of brokerages have recently weighed in on RXRX. SVB Leerink lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a report on Monday, January 23rd. The Goldman Sachs Group boosted their price objective on shares of Recursion Pharmaceuticals from $8.00 to $9.00 and gave the stock a "neutral" rating in a report on Wednesday, November 9th.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Baillie Gifford & Co. increased its stake in shares of Recursion Pharmaceuticals by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 24,820,850 shares of the company's stock worth $191,369,000 after buying an additional 3,226,157 shares during the period. Bank of New York Mellon Corp increased its position in Recursion Pharmaceuticals by 26.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 503,941 shares of the company's stock valued at $5,362,000 after purchasing an additional 104,588 shares during the period. Teachers Retirement System of The State of Kentucky purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at $1,750,000. Advisory Research Inc. increased its position in Recursion Pharmaceuticals by 56.6% during the 3rd quarter. Advisory Research Inc. now owns 96,803 shares of the company's stock valued at $1,030,000 after purchasing an additional 34,999 shares during the period. Finally, BNP Paribas Arbitrage SNC purchased a new position in Recursion Pharmaceuticals during the 3rd quarter valued at $1,139,000. 63.62% of the stock is owned by hedge funds and other institutional investors.
About Recursion Pharmaceuticals
(Get Rating)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.
See Also
- Get a free copy of the StockNews.com research report on Recursion Pharmaceuticals (RXRX)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.